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There is a growing body of scientific evidence that the health of the microbiome (the trillions of microbes
that inhabit the human host) plays an important role in maintaining the health of the host and that disruptions
in the microbiome may play a role in certain disease processes. An increasing number of research studies
have provided evidence that the composition of the gut (enteric) microbiome (GM) in at least a subset
of individuals with autism spectrum disorder (ASD) deviates from what is usually observed in typically
developing individuals. There are several lines of research that suggest that specific changes in the GM could be
causative or highly associated with driving core and associated ASD symptoms, pathology, and comorbidities
which include gastrointestinal symptoms, although it is also a possibility that these changes, in whole or in
part, could be a consequence of underlying pathophysiological features associated with ASD. However, if the
GM truly plays a causative role in ASD, then the manipulation of the GM could potentially be leveraged as a
therapeutic approach to improve ASD symptoms and/or comorbidities, including gastrointestinal symptoms.
One approach to investigating this possibility in greater detail includes a highly controlled clinical trial in which
the GM is systematically manipulated to determine its significance in individuals with ASD. To outline the
important issues that would be required to design such a study, a group of clinicians, research scientists, and
parents of children with ASD participated in an interdisciplinary daylong workshop as an extension of the
1st International Symposium on the Microbiome in Health and Disease with a Special Focus on Autism (www.
microbiome-autism.com). The group considered several aspects of designing clinical studies, including clinical
trial design, treatments that could potentially be used in a clinical trial, appropriate ASD participants for
the clinical trial, behavioral and cognitive assessments, important biomarkers, safety concerns, and ethical
considerations. Overall, the group not only felt that this was a promising area of research for the ASD
population and a promising avenue for potential treatment but also felt that further basic and trans-
lational research was needed to clarify the clinical utility of such treatments and to elucidate possible
mechanisms responsible for a clinical response, so that new treatments and approaches may be discovered and/
or fostered in the future.
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A
n increasing number of research studies have pro-
vided evidence that the composition of the gut
(enteric) microbiome (GM) in autism spectrum
disorder (ASD), in at least a subset of individuals, de-
viates from what is expected in typically developing
individuals (14). However, there is not a clear consensus
regarding possible cause(s) and consequence(s) of these
perturbations. There are several lines of research that
suggest that specific changes in the GM may be causative
in driving core and associated ASD symptoms and gastro-
intestinal (GI) symptoms, although, at this point in time,
this hypothesis has not been satisfactorily and/or system-
atically evaluated. If such a hypothesis is true, then mani-
pulation of the GM could potentially be leveraged as
a possible therapeutic approach to improve core and
associated ASD symptoms and also address important
comorbid medical factors that may be present in some
children with ASD, such as GI symptoms. One approach
of investigating this possibility in greater detail includes
clinical studies in which the GM is systematically mani-
pulated. Such an approach could answer three important
questions: first, whether there is a connection between
ASD symptoms and alterations in the GM; second, whether
manipulations can be safely used as a therapeutic ap-
proach for treating ASD; and third if putative mechanisms
responsible for such an effect can be better understood.
To this end, on Friday, June 27, 2014, a GM Workshop
at Arkansas Children’s Hospital Research Institute was
held. The working group included clinicians, research
scientists, and parents of children with ASD (see Table 1).
This workshop was an extension of the 1st International
Symposium on the Microbiome in Health and Dis-
ease with a Special Focus on Autism (www.microbiome-
autism.com). The aim of this workshop was to consider
the design of a clinical trial focused on determining
whether children with ASD can respond to therapy aimed
at modulating and/or manipulating the GM.
The emerging interest of the microbiome in
neurodevelopmental disorders
There is a growing body of clinical and basic science
evidence that the GM (the trillions of microbes that
inhabit the human digestive tract) affect immune and
metabolic function (57) as well as modulate gene expres-
sion through epigenetic mechanisms (8, 9) that may initiate
and exacerbate ASD pathophysiology and/or symptoms
(1012). Emerging research has found that GM and its
metabolic byproducts play a major role in normal brain
and behavioral development (13), and that these factors
are altered in persons with ASD (14) [see accompanying
papers by Krajmalnik-Brown et al. (14), in this issue].
Thus, alterations and/or perturbations in the GM may
contribute to core and associated ASD symptoms by affect-
ing behavior and brain function (12, 1519) and modulating
the expression of ASD-associated genes (20). Although
this field is in its infancy, rapidly emerging technological
advances have given us an increasing amount of relevant
data, thereby increasing the possibilities of creating new
prophylactic and therapeutic interventions.
Defining the question
The study of the relationship between ASD and the GM
should be conducted very carefully in the manner in which
one carefully poses the question and designs the study. The
group suggested using a Patient/Populations, Intervention,
Comparison, and Outcome (PICO)-like formulation for
any question. PICO is a method for formulating a research
question, particularly for systematic literature reviews.
A PICO like method is essential for creating a well thought
out scientific study.
Table 1. List of attendees
Attendee Institution
Richard E. Frye Arkansas Children’s Hospital Research Institute, Little Rock, AR, USA
John Slattery Arkansas Children’s Hospital Research Institute, Little Rock, AR, USA
John Rodakisa N of One: Autism Research Foundation, Dallas, TX, USA
Stephen Kahler Arkansas Children’s Hospital Research Institute, Little Rock, AR, USA
Jana Jenningsa Private Practice, Benton, AR, USA
Ellen Boltea N of One: Autism Research Foundation, Dallas, TX, USA
Carl E. Cerniglia National Center for Toxicological Research, Jefferson, AR, USA
Tore Midtvedt Karolinska Institutet, Solna, Stockholm, Sweden
Emma Allen-Vercoe University of Guelph, Guelph, ON, Canada
William Parker Duke University, Durham, NC, USA
James Adamsa Arizona State University, Tempe, AZ, USA
Rosa Krajmalnik-Brown Arizona State University, Tempe, AZ, USA
Derrick MacFabe Western University, London, ON, Canada
Susan Swedo National Institutes of Mental Health, Bethesda, MD, USA
Jill James Arkansas Children’s Hospital Research Institute, Little Rock, AR, USA
aIndicates parent of child with ASD.
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Trial design
Subgroups
Clinical trials in children with ASD have been extremely
challenging for many reasons, including the fact that
there is significant heterogeneity in the ASD phenotype
without much agreement on how different endopheno-
typic subgroups should be defined. Thus, the working
group believed that selection of specific ASD subgroups
would be best based upon the goal of the trial. This is
discussed in more detail in the Selection of Participants
section below.
Concurrent treatments
Children with ASD have a wide range of medical abnor-
malities, which require various behavioral, psychiatric, and
biomedical treatments that can be difficult to equate across
subjects and challenging to keep constant throughout a
clinical trial. The working group felt that it was important
to carefully control concurrent treatments and keep such
treatments stable. The working group felt that one of the
most difficult factors to control might be educational and
behavioral therapy and schooling. Factors such as summer
and winter breaks, changing of therapists, and changing of
the content of therapeutic programs, especially as symp-
toms worsen or improve, all have the potential to be
confounding factors. Although it would be optimal to
tightly control the behavioral and educational therapy, it
would be very difficult and expensive. Although approaches
such as timing study entry to the start of school is possible,
this could significantly limit the recruitment window and
could pose a challenge to completing a study within a
reasonable time frame. The working group felt that
another critical factor was diet, especially considering
that many children with ASD are on special diets or have
very limited diets which can influence the GM.
Trial length
Length of any clinical trial depends on the treatment
selected and its effect on the putative underlying biolo-
gical mechanism(s). Since the mechanisms involved in alter-
ing the GM likely involve a cascade of biological events, a
number of factors need to be considered. The working
group felt that one of the most important considerations
is the timeframe in which the composition and functions
of GM will change by the selected treatment. Whereas
treatments that change the GM composition may take
significant time, other treatments that change the GM’s
influence on metabolic, immune, and/or epigenetic fac-
tors may occur more rapidly. The timeline for changes
in symptoms associated with ASD also needs to be
considered. ASD is currently considered to be a life-long
disorder with a minority of individuals with ASD attain-
ing optimal outcomes. Even those that demonstrate op-
timal outcomes still exhibit subtle difficulties in language
and executive function (2123). Thus, changes in ASD
symptoms can occur over days, months, or years. While
some core or associated ASD symptoms may change
or improve in the short-term, other important symp-
toms that involve complex cognitive constructs, such as
socialization, may take significant time to change. How-
ever, timing of any trial also depends on the aim of the
study. For example, the working group felt that it might
be adequate to conduct short-term trials if the question
focused on biological mechanisms using biomarkers as
the outcome variables, whereas trials that assess behavior
or cognition may require much longer time periods and
long-term follow-up.
Efficacy versus effectiveness versus mechanistic trials
Efficacy trials that demonstrate the significance of a
treatment in a carefully controlled setting are the gold
standard for proving that a treatment can work. However,
the working group felt that other types of trials, such
as an effectiveness trial that measures the benefit of a
treatment under ‘real world’ settings, are equally impor-
tant. The fact that the practical aspect of treating a child
with ASD is very complex coupled with the high degree
of heterogeneity within the ASD spectrum highlights the
possibility that effectiveness trials could be significantly
advantageous. Alternatively, given the complicated nature
of ASD, the working group felt that understanding the
underlying biological mechanisms behind any treatment
could be of upmost importance, especially if high-quality
biomarkers were used.
Blinded versus open-label
Although it was recognized that blinded, particularly
double-blind placebo-controlled (DBPC) studies are the
gold standard for proving efficacy of a treatment, the
working group also felt that given that the exact
mechanism of disease and action of the treatment are
still unclear for many GM treatments, open-label ex-
ploratory trials that examine biological mechanisms of
response and provide information to define biomarkers
and characterize responders could be equally important
and could help guide future DBPC trials.
Parallel versus cross-over trials
Cross-over trials can be very useful for controlling
individual differences when significant individual hetero-
geneity exists. However, cross-over studies require signifi-
cant assumptions that may not be wise to accept in the
ASD population for several reasons. First, it is assumed
that the placebo will not change the outcome measure. This
assumption provides power to a cross-over study because
the participant serves as their own control, reducing the
need to match an individual in a control group with an
individual in the treatment group on particular character-
istics. However, many children with ASD, especially those
that are medically complex, demonstrate wide variability
in ASD symptoms over time with waxing andwaning in the
Autism and the enteric microbiome
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severity of their symptoms. The reasons for these beha-
vioral fluctuations are multifactorial with little known
evidence regarding the ability to predict these variations.
These factors complicate the ability of an individual
patient being used as their own control unless such
variability is taken into account. Second, if the active
treatment is the first arm of a cross-over study, it is
assumed that after a relatively short washout period, the
effect of the treatment will be lost and the participants
in the trial will return to their own respective baseline.
However, if the treatment results in a major change in GM
composition, a short washout period may not be sufficient
time to recover to the baseline GM (if ever). Thus, given the
fact that most treatments will influence the composition
and functions of GM, the working group recognized that
in most instances it is probably best to use a parallel design.
Treatments that may alter the GM
Many treatments for children with ASD that are already
in use have the potential to change the GM. The specific
effect on the GM of many of these treatments, such as
special diets, may not be clear, while other treatments,
such as antibiotic therapy, may have predictable effects on
specific bacteria and/or their metabolites, but unknown
downstream long-term effects. Other treatments, such
as fecal microbiota transplantation (FMT), have been
well established for other conditions such as Clostridium
Difficile overgrowth but are still considered experimental
for ASD. Below is a summary of treatments that may
manipulate the GM and may be appropriate for study.
Treatments that reduce specific gut microbiome
components
Antibiotics
Several studies have suggested that children with ASD
have a history of increased antibiotic use for recurrent
infections prior to their diagnosis (24) and other studies
have suggested that antibiotic use during pregnancy is
linked to the development of ASD (25). Some groups
have even hypothesized that use of specific antibiotics
early in life could be causative for ASD (26) and others
have suggested that antibiotic use early in life facilitates a
vicious cycle between immune system impairment and
dysbiosis (27).
Vancomycin and metronidazole are two antibiotics
used to treat ASD symptoms both within clinical and
research studies that are believed to target specific GM
bacteria (28). Vancomycin broadly targets Gram-positive
bacteria, including Gram-positive anaerobic bacteria
such as those that are members of the Clostridium genus,
and is believed to have a favorable safety profile when
administered orally since, under normal physiological
circumstances, vancomycin is not absorbed from the GI
tract into the circulation to any significant extent (29, 30).
Metronidazole also targets similar GM bacteria, but
since it is systematically absorbed, it is felt to have a
less favorable safety profile because of the possibility of
systemic adverse effects (28).
In a small, partially blinded 8-week clinical trial of
vancomycin conducted in the United States on children
with ASD, significant GI symptoms and high irritability,
temporary effectiveness was found for treating ASD
symptoms in 8 of 11 participants (31). Approximately
half of participants had an initial burst of hyperactivity
lasting 14 days. Vancomycin levels were measured in the
patients with the highest levels of intestinal permeability
to assure that there was no absorption of vancomycin,
although the data remain unpublished.
The therapeutic response to vancomycin is supported
by the propionic acid rodent model of ASD (12, 1520)
and may in part or in total be related to mitochondrial
dysfunction resulting from the overproduction of short-
chain fatty acid fermentation products such as propionic
acid from GM bacteria [see accompanying paper by Frye
et al. (32) in this issue]. At the same time, it is possible
that an aberrant immune response toward particular
components of the GM or aberrant gut epithelial barrier
function is responsible for the therapeutic response to
vancomycin [see accompanying paper by Bilbo et al. (33)
in this issue].
When discussing the use of vancomycin, even in a
clinical research setting, it is of the utmost importance to
stress that vancomycin-resistant enterococcus (VRE) is
a very serious health concern. If a future clinical trial
confirms a clinically meaningful response to vancomycin
in children with ASD, then the findings can be applied to
other treatments in order to prevent vancomycin overuse.
Indeed, the use of vancomycin in a clinical trial could be
very useful for mechanistically demonstrating the beha-
vioral, biochemical, and microbial effects of manipulat-
ing the GM, and to learn and produce new hypotheses,
but may not be a viable long-term solution. Other less
problematic treatments may be developed based on the
knowledge gained from such a trial.
Antibiotics which do not specifically target Clostridium
genus are used to treat ASD symptoms under the diag-
nostic umbrella of Pediatric Autoimmune Neuropsychiatric
Disorder Associatedwith Streptococcal infections (PANDAS),
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), or
chronic Lyme disease (34, 35). These antibiotics have well-
known effects on pathogenic organisms such as Streptococcus
and Borrelia but can disrupt healthy gut bacteria, resulting in
dysbiosis. Antibiotics can also have direct effects on human
host cells. Some have speculated that common antibiotics,
such as aminoglycosides, may either be triggering or
improving ASD symptoms by disrupting polymerase func-
tion (36). Likewise, chronic administration of beta-lactam
antibiotics for routine pediatric infections may impair gut
and renal carnitine transport, possibly worsening a relative
Richard E. Frye et al.
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carnitine deficiency and causing mitochondrial dysfunction
(12, 15, 16).
One of the attendees indicated that parents of children
with ASD seem to support the idea that some children
with ASD may be positive responders to antibiotic treat-
ments when prescribed for PANDAS/PANS or infections
in an informal social media discussion [see accompanying
paper by Rodakis in this issue]. Other attendees were
aware of at least one unpublished small, open-label trial
that demonstrated positive effects of antibiotics on ASD
symptoms. However, published evidence supporting these
observations are lacking, underlying the need for well-
controlled, objective clinical studies to document any
effect on ASD symptoms and/or to understand under-
lying mechanisms. Furthermore, given the public health
concerns of antibiotic resistance and health risks asso-
ciated with antibiotic misuse and overuse, it is critical
to determine if this practice is able to provide clinical
benefits.
Antifungals
Children with ASD are treated in clinical practice with
antifungal agents despite the lack of scientific evidence of
fungal overgrowth. One study that specifically examined
yeast in the gut demonstrated no difference between ASD
and typically developing children (37). However, it should
be noted that detection of yeast strains is technically
challenging, potentially resulting in a high false negative
rate. A national survey by the Autism Research Institute
(Table 2) found that parents reported that antifungal
therapy with Diflucan or Nystatin was often beneficial
and rarely worsened symptoms (38). It should be noted
that antifungal treatments have known toxicity and may
require monitoring of liver transaminases for safety.
Caveats
The working group noted that the treatments that could
change specific components and diversity of the GM
are commonly used in the treatment and management of
children with ASD. The evidence for the effectiveness
of these treatments for improving ASD symptoms is
very limited. This highlights the need for well-controlled
clinical trials. Several challenges were noted in this area of
ASD treatment research. First, there may be subgroups
of children with ASD who respond positively or nega-
tively to these treatments and the treatments themselves
may have a significant carry-over effect meaning that long-
term observation may be needed. Furthermore, antibiotic
resistance is a major health concern for the United States
and other industrialized nations, making the safety of
long-term and repeated treatments with these agents
problematic, both to the patient and to the hospital,
clinics, and the general population.
Treatments that replace gut microbiome
components
Fecal microbiota transplantation
FMT is an intervention in which the fecal microbiota from
a donor is delivered to a recipient in an attempt to replace a
dysbiotic GM with a healthy one. It is highly efficacious
(approximately 92%) in curing recurrent C. difficile infec-
tions (39). There is interest in using it in a number of
disease states which appear to be associated with disrup-
tion of the GM. These disorders include GI diseases such
as inflammatory bowel disease, irritable bowel syndrome,
and chronic constipation as well as non-GI diseases such
as autoimmune diseases, chronic fatigue syndrome, and
obesity (40). Further safety and efficacy studies in clini-
cally controlled trials are necessary to evaluate the use of
FMT. For example, recently, new-onset obesity was observed
in a FMT recipient for recurrent C. difficile infection after
transplantation from an obese donor (41). Thus, current
FMT studies are very careful regarding the selection of
donors. Given the growing evidence for imbalance in the
GM in ASD, there is an increasing interest in using FMT
in ASD. Several attendees are currently involved in FMT
treatment research for ASD and other disorders. However,
the attendees felt that this approach is still in need of
refinement, particularly in understanding the type of
transplant, the delivery system to use, dosage, and dura-
tion of treatment as well as the need for pretreatment use of
antibiotics and bowel-cleansing regimes [see accompany-
ing papers by Krajmalnik-Brown et al. (14), and Toh and
Allen-Vercoe (42) in this issue].
Helminths
There is a growing body of literature indicating that
changes in the environment have resulted in a rise in
immune disease over the past century [see accompanying
paper by Bilbo et al. (33) in this issue]. One significant
change that is underappreciated is the loss of exposure to
eukaryotic, multicellular organisms living in the gut (e.g.
worms called helminths) as a result of the widespread use
of technological advances such as indoor plumbing, water
treatment facilities, and modern food processing facilities
(43). Our immune system has evolutionarily adapted over
Table 2. Autism Research Institute survey of parent ratings of treatment efficacy
% Worse % No change % Better Number of reports
Antifungals: Diflucan 5 34 62 1,214
Antifungals: Nystatin 5 43 52 1,969
Candida diet 3 39 58 1,141
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millennia to protect our bodies from these gut dwelling
organisms and it is believed by some that the sudden loss
of these complex multicellular organisms may have de-
stabilized the immune system, leading to an increased
reactivity to environmental stimuli and, in some cases, to
the body itself. This view, originally labeled the ‘hygiene
hypothesis’, is more appropriately known as the ‘biome
depletion theory’ (44). To combat this destabilization of
the immune system, researchers have investigated treat-
ments with helminths such as the pig whipworm, Trichuris
suis, which can stimulate the enteric immune system but
cannot maintain prolonged residence in the bowel. The
idea of the use of this treatment in ASD has recently been
introduced (45) and clinical trials are currently underway.
Probiotics
Probiotics are living microorganisms, usually lactic-acid-
producing bacteria, which are believed to be beneficial to
health. Probiotics are widely used for children with ASD
and there is growing excitement as a result of recent studies
on animal models of ASD (46). Specifically, animal re-
search suggests that treating the maternal immune acti-
vation mouse model, which is an animal model with
behavioral and metabolic characteristics similar to ASD
and alterations in the enteric microbiome, with a humanly
derived strain of Bacteroides fragilis improves metabolic,
enteric microbiome, and behavioral abnormalities, sug-
gesting that this might be a promising treatment for
children with ASD. The theorized mechanisms by which
B. fragilis produces a treatment effect, at least in a mouse
model, is through ameliorating enteric microbiome im-
balances (47) including upstream and downstream by-
products which modulate behavior. Other studies not
related to ASD have demonstrated that some probiotic
strains can influence the immune system (48, 49), at least
for a certain period of time, and metabolic abnormalities
such as redox imbalances (50).
Although the working group is supportive of the use
of probiotics, it should be highlighted that commercial
probiotics vary considerably in their quality, composi-
tion, and efficacy, and clinical studies are lacking in
children with ASD regarding their effectiveness. There
are several limitations of commercial probiotics that
should be noted. First, they contain only a tiny fraction
of the total bacteria in the gut and the bacteria they do
contain are limited in diversity compared to the broad
number and types of bacteria in the human gut. For ex-
ample, the human gut contains more than 1,000 different
strains of bacteria while commercial probiotics usually
contain less than 10 strains of bacteria. Second, they
rarely contain obligate anaerobes that constitute a mean-
ingful percentage of the typical GM. Third, since they
are derived from milk, the human GM is not a natural
environment for these organisms.
Unprocessed foods
Certain natural, unprocessed foods have become popular
as treatments for children with ASD. Fermented foods and
raw milk such as camel’s milk have natural bacteria and
prebiotics that may, at least theoretically, influence the GM
in a variety of ways. Some interesting preliminary studies
suggest some benefit of camel’s milk in children with ASD.
In one case study, the author claims that the consumption
of raw camel’s milk heralded the start of a 6-year im-
provement in ASD symptoms for his son (51). One DBPC
study demonstrated that 2 weeks of either raw or boiled
camel’s milk consumption resulted in significant improve-
ment in biochemical measures of oxidative stress, including
glutathione, superoxide dismutase, and myeloperoxidase
as well as ASD symptoms as indexed by the Childhood
Autism Rating Scale (CARS), while cow’s milk did not
result in such improvements (52). The fact that the boiled
camel’s milk had a similar effect as compared to the raw
camel’s milk suggests that the effect of camel’s milk was not
due to live bacteria, as some believe. A second DBPC study
found that both raw and boiled camel’s milk resulted in
improvement in thymus and activation-regulated chemo-
kine serum levels, but that only raw camel’s milk resulted in
improvement in the CARS as compared to cow’s milk (53).
The use of cow’s milk as a control could be a significant
factor in these studies as cow’s milk is believed to stimulate
immune function and potentially increase oxidative stress.
Thus, using cow’s milk as a comparison may not be
optimal to answer the question whether the effects seen
in these studies are due to camel’s milk specifically or due
to the lack of cow’s milk. Indeed, milk-free diets, including
casein-free diets, are believed to be beneficial in children
with ASD. Bovine milk products can stimulate the
production of the folate receptor a autoantibodies (54).
This autoantibody can bind to the folate receptor a and
block the transport of folate into the brain resulting in
depressed folate concentration in the brain (55). Unpub-
lished laboratory studies suggest that the folate receptor a
exists at the same level in camel’s milk as compared to cow’s
milk (Dr Edward Quadros, personal communication).
Fermented foods
Information about the use of fermented foods, such as
keffirs, to treat ASD is purely anecdotal, so scientific evi-
dence for these treatments are currently lacking. Thus,
although there are reasons to believe that these treat-
ments could be useful, at least in some children with
ASD, further research is needed to determine whether
there is any true benefit to these treatments, and, if so,
whether such benefits are due to changes in the micro-
biome and/or related to other biological mechanisms.
Treatments that may change the gut environment
Dietary treatments
It is not uncommon in ASD for several specific dietary
interventions to be prescribed by medical professionals.
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Furthermore, it is not uncommon for parents to independ-
ently implement specific dietary changes independent
of medical recommendations. Such diets (i.e. gluten-free/
casein-free, specific carbohydrate diet, elemental diet)
contain various types and qualities of carbohydrates
while other diets, such as the modified Atkin’s diet, limit
carbohydrates. Other diets empirically attempt to limit
refined carbohydrates, foods containing additives, such as
the food preservative propionic acid, or artificial sweet-
eners, which have recently been shown to alter the GM,
short-chain fatty acid production, and lipid metabolism
(12, 15, 56, 57). In contrast, other approaches attempt to
normalize an otherwise self-limited diet. There is pre-
liminary evidence for effectiveness of some of these diets
in ASD. Small studies provided inconsistent evidence
for the effectiveness of the gluten-free, casein-free diet
(58, 59), while a larger single-blind study provides more
promising results (60). There is enthusiasm for the
modified Atkin’s diet (61) for children with ASD, espe-
cially for those with concurrent epilepsy (62). Some of
these diets have been used for individuals with inflam-
matory bowel disease, but studies are inconsistent (63).
Diet can have a profound effect on the composition and
metabolic products of the GM (64) and on the immune
system (65), but little is known about the correlations
between these special diets and the GM in ASD. Clearly
this is an interesting area of clinical research that is still
very preliminary. Well-designed clinical trials focusing
on diets in ASD may be particularly fruitful for under-
standing the mechanism of action of these diets, espe-
cially if they involve carefully characterization of the
GM. Given the likely heterogeneity of ASD, a helpful
approach may be to focus attention on dietary responders
in larger controlled clinical trials.
Digestive enzymes
Given that children with ASD appear to have defects in
certain intestinal digestive enzymes, particularly enzymes
responsible for carbohydrate digestion (1), it is logical
that supplementation of digestive enzymes may be useful,
especially since carbohydrates that go undigested in the
small bowel will be transported to the colon where they
can stimulate bacterial fermentation. However, clinical
treatment studies using digestive enzymes report mixed
results. In an open-label study of 46 patients, a digestive
enzyme containing Caso-Glutenase 10,000 AU, Brome-
lain 230 BTU, Acid Fast Protease 100 SAPU, Lactase 330
LacU, Phytase 125 U, and Galactose 100 mg was given
with meals (66). The 22 patients who completed the study
showed significant gains in several ASD-related symptoms.
However, a DBPC cross-over study of 43 children treated
with a digestive enzyme containing peptidase and pro-
teases only during one meal per day failed to demon-
strate improvements in ASD symptoms (67). Although a
DBPC design is the gold standard as compared to the
open-label study, clearly the two studies used different
approaches with the open-label study using a mixture of
enzymes that digests both proteins and carbohydrates
with every meal and the DPBC using a digestive enzyme
that only digests proteins and only with one meal.
Unfortunately, the open-label study provided very biased
results as only the patients that continued the treatment
were analyzed. Clearly this is an interesting area of treat-
ment research that deserves greater attention.
Vitamins
Vitamins can be consumed or made more bioavailable
by the GM. Deficiencies in vitamins can change the
GM composition and the GM composition can change
the requirement for specific vitamins and minerals. For
example, Lactococcus spp have been associated with folate
biosynthesis in animal studies (68) and human omnivores
metabolize carnitine into a proatherogenic compound,
trimethylamine-N-oxide, through a microbiota-dependent
mechanism whereas vegetarians or vegans do not meta-
bolize carnitine in this way (69). Likewise biotin and B12
are essential cofactors for propionic acid breakdown,
and dietary deficiencies of these vitamins may further
impair propionic acid and carnitine metabolism and
contribute to ASD-associated mitochondrial dysfunction
(12). One study measured levels of all vitamins in children
with ASD and found that they were significantly lower
in biotin compared to controls (70). Biotin is a vitamin
which is produced by GM bacteria in amounts that are
comparable to dietary intake, and a follow-up treatment
study with a vitamin/mineral supplement found that
initial low levels of biotin or vitamin K (also produced
in substantial amounts by GM bacteria) was highly
correlated with degree of improvement resulting from
the treatment (71). Collectively, this suggests that children
with ASD may have low amounts of the GM bacteria
that produce biotin and may benefit from biotin supple-
ments. Clearly, the interactions between the GM and
vitamin requirements and bioavailability are complex and
require further study.
Toilet training
Many children with ASD have difficulty with toilet train-
ing and may be withholding bowel movements leading to
functional constipation. An abnormal frequency in bowel
movements can result in a change in the GM and in the
production of microbial metabolites (12, 15). Conversely,
changes in the GM can result in constipation and dif-
ficulty in toilet training.
Participants: defining subgroups
Properly screening and selecting participants is of upmost
importance in clinical studies.
First, it is important to carefully define the inclusion
criteria so that the selected study cohort is optimal.
Children with ASD should be diagnosed carefully,
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preferably with a gold-standard tool such as the Autism
Diagnostic Observation Scheduled (ADOS) and/or the
Autism Diagnostic Interview  Revised (ADI-R) by a
certified research reliable rater.
Second, it is important to exclude those children
with complicated medical conditions or medications
that could interfere with the study. Examples of possible
exclusion criteria include
. Inborn errors of metabolism
. Failure to thrive
. Epilepsy
. Inflammatory bowel disease
. PANDAS/PANS
. Chronic infections
. Recent antifungal, antiviral, and/or antibacterial
medications
. Treatments that alter the GM such as pre/probiotic
usage or special diets
. Immunosuppressant medications
. High-dose vitamins since these treatments may alter
both the GM and metabolism
. Puberty
. An inability to maintain other therapies constant
throughout the study
. A caretaker who is not able to comply with protocol
. Specific genetic abnormalities, such as Fragile X
syndrome
Finally, it is important to either select a group of
children with ASD who are hypothesized to respond most
significantly to a treatment or to stratify the participants
into two or more subgroups to understand whether spe-
cific factors are important in predicting treatment re-
sponse. For example, Finegold et al. suggest that children
with regressive ASD were more likely to have a wide
variety of non-spore-forming anaerobes and microaero-
philic bacteria in their feces (72), so children with regres-
sive ASD may be an optimal group for study. Other
possibilities include children with a history of positive
response to specified classes of antibiotics, those with
significant GI symptoms, or those with high irritability
scores. For children with waxing and waning symptoms, it
might be best to follow them longitudinally to determine
the optimal time to start the intervention.
Behavioral and cognitive measures
Baseline characteristics
It is of the upmost importance to carefully characterize
participants at baseline. The following baseline measures
were proposed:
. ASD diagnosis using gold-standard instruments
such as the ADOS and/or ADI-R.
. Assessment of social function using an instrument
such as the Social Responsiveness Scale.
. Measurement of intellectual and/or developmental
functioning. Many intelligence tests have been used
with children with ASD, but the limitations in
language commonly associated with ASD can cause
a downward bias in intellectual quotient scores
leading some to suggest that non-verbal intellectual
testing should be used in children with ASD to
account for this potential confounding factor.
. An index of development such as the Adaptive
Behavioral Composite from the Vineland Adaptive
Behavioral Scale.
. Dietary history with a comprehensive assessment
due to dietary effects on the GM.
. Psychiatric history to look for important comorbidities.
. Comprehensive medical history looking for impor-
tant medical factors such as GI symptoms pre- and
post-ASD diagnosis, as well as other important
factors such as oral antibiotic usage during the
pre- and postnatal periods, probiotic usage, delivery
method (vaginal or C-section), and neonatal com-
plications and hospitalization duration.
. Developmental profile must be examined in detail
with a clear and detailed understanding of the
timing of the development of ASD symptoms and
whether regression in any skills occurred. Any
trigger that may have caused regression should be
examined in detail. Regression can be investigated
using a standardized method (73).
. Executive function is an important deficit in chil-
dren with ASD, so specific age-appropriate instru-
ments such as the Delis-Kaplan Executive Function
System should be considered.
Outcome measures
Important quantitative outcomes measures should be
employed in any study of the microbiome in ASD.
Measures that were felt to be important included:
. Autonomic Tone: The autonomic nervous system has
been shown to be disrupted in children with ASD
and is closely linked to GI function (74). Measures
such as pupillometry (75) and skin conductance
(76), among other autonomic nervous system mea-
sures, have been used to document abnormal
autonomic nervous system reactivity in individuals
with ASD.
. Behavior: Behavioral dysregulation is a key symp-
tom of functional impairment in children with ASD
and it is measured in various ways including care-
giver questionnaires such as the Aberrant Behavior
Checklist (ABC) which has been used in multiple cli-
nical trials and the Children’s Yale-Brown Obsessive
Compulsive Scale (Y-BOCS) (77). Other studies
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have used a visual analog scale for rating of parental
selected target behaviors (78). Clinician rated Clin-
ical Global Impression (CGI) Scale is common, but
a new scale specific for ASD behaviors known as the
Ohio Autism Clinical Impression Scale (OACIS) may
be more specific. The OACIS (79), previously known
as the OSU Autism Rating Scale (80), has been shown
to be reliable across cultures (81) and has been suc-
cessfully used in several ASD clinical trials (8284).
Other studies have carefully coded behaviors based
on video recordings using rating scales adapted from
animal studies (85). Actigraphy can also be used to
objectively monitor behavior and activity level dur-
ing the daytime. Finally, eye-tracking paradigms can
be used to detect changes in visual attention (86).
. Fine Motor: Fine motor function is often disrupted
in children with ASD. Examining changes in hand-
writing or in the ability to copy a picture can
demonstrate fine motor changes.
. Sleep: Sleep is commonly disrupted in children with
ASD. Studies have used several methods for mea-
suring sleep. One of the most objective means for
measuring sleep quality is actigraphy (87) that appears
to be superior, especially for measuring nighttime
wakening, as compared to parental sleep diaries (88).
Two questionnaires have been used to measure sleep
symptoms in ASD: the Modified Simonds and
Parraga Sleep Questionnaire and the Children’s Sleep
Habits Questionnaire (89).
. Gastrointestinal Symptoms: Most studies create their
own unique GI symptoms scales, although a few
standardized scales have been developed. One study
used a simple nine question Gastrointestinal Sever-
ity Index (GSI) (90) that has been shortened to six
key questions (GSI-6) in another study (37). Others
have developed very detailed questionnaire such
as the Questionnaire on Pediatric Gastrointestinal
Symptoms (91) while others have used the Gastro-
intestinal Symptom Rating Scale (92). Scales that
measures stool characteristics such as the Bristol
stool scale could also be useful to use on a daily
basis during a study.
Biomarkers
Biological sample collection
The working group felt that it was critical to standardize
any stool collection protocol such as obtaining the first
morning stool or obtaining a 24 h collection. Timing of
biomarker collection may be critical as research studies
have demonstrated diurnal oscillations in the composi-
tion and function of the GM (93). It is also important
to ensure that specimens are immediately frozen at 20
to 808C. Of course, GI issues which are common in ASD,
such as chronic constipation and chronic diarrhea, can
complicate any collection, standardization, and compar-
ison across individual samples.
Microbiota identification
The various conventional and culture-independent meth-
ods to determine the microbiota content of the GM have
their individual strengths and weaknesses. Rapid improve-
ments and cost reductions in molecular microbiome iden-
tification methods make such investigations attractive for
clinical studies. Such techniques are essential since anae-
robic bacteria are difficult to culture in the lab. This has
led to the popularity of techniques that identify the ge-
netic fingerprint of bacteria, for example, variable re-
gions of 16S ribosomal RNA gene sequences. Techniques
range from semiquantitative methods such as temperature
gradient gel electrophoresis, denaturing gradient gel elec-
trophoresis, and terminal restriction fragment length
polymorphisms as well as quantitative genetic techniques
such as microarrays and direct sequencing. 16S ribosomal
RNA genes are the most popular targets because they are
specific to bacteria (and archaea), and not found in human
cells. Shotgun metagenome sequencing methods sequence
all genetic material in the entire microbiome, allowing
more detailed classification of the bacterial taxonomy
and the genetic potential of a given microbiome commu-
nity. Next generation sequencing methods have lowered
sequencing costs and enable megagenomics to become
cost-effective, although a bottleneck remains in the time
required for post-sequencing analysis. Bioinformatics
methods that can predict metagenomes using 16S riboso-
mal RNA gene information such as Phylogenetic Investi-
gation of Communities by Reconstruction of Unobserved
States (PICRUSt) (94) are also available and when
used correctly could save a significant amount of time
and money.
Metabolic biomarkers
Stool, urine, and blood biomarkers of metabolic products
of enteric bacteria have been described. Although there is,
as yet, only preliminary data to support their use as GM
biomarkers, further studies could validate these ap-
proaches. Both targeted methods which identify specific
compounds and untargeted metabolomics methods have
been used.
Urinary HPHPA
3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA)
has been shown to be increased both in children with ASD
and in adults with recurrent C. difficile infections, and was
found to decrease in a patient with acute schizophrenia
after treatment with oral vancomycin leading the authors
to suggest that this is a valid biomarker for the Clostridium
genus (95). Although this preliminary data are interesting,
clearly further studies are needed to validate this biomar-
ker as specific to Clostridium spp. and determine its role in
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ASD pathophysiology. Complicating these findings is
the fact that the taxonomy of the Clostridium genus is
currently in a state of flux and not clearly defined.
Urine p-cresol
p-cresol (4-methylphenol) is an organic aromatic com-
pound that is not produced by the body but is a relatively
common compound that can be absorbed through the
skin, GI, and respiratory systems. It is also produced by
enteric bacteria including C. difficile, C. scatologenes,
Lactobacillus spp., Pseudomonas stutzeri, and Pseudomonas
mendocina (96). Studies have found that urinary p-cresol
is elevated in children with ASD younger than 8 years of
age (particularly females), those who are more severely
affected, and those with regressive ASD (97). Further
analysis found that fractions of p-cresol, p-cresylsulfate,
and p-cresylglucuronate were also elevated in children with
ASD (96).
Acyl-carnitines
Studies have linked a pattern of abnormal elevations
in acyl-carnitines, biomarkers of fatty-acid metabolism,
to metabolic changes associated with excess exposure
to propionic acid in animal models of ASD and have
demonstrated that this same pattern is found in children
with ASD and mitochondrial dysfunction (12, 15, 16).
Untargeted metabolomics
New metabolomics techniques can detect many metabo-
lites produced by the microbiota, which can influence
host physiology such as choline metabolites, secondary
bile acids, phenols, and short-chain fatty acids (98).
Immune function
The microbiome is closely associated with immunological
abnormalities and diseases. Several studies have demon-
strated that changes in the GM modulate cytokines and
immune cells (99, 100). Such immune measures have the
potential to be used as biomarkers of microbiome activity
and vice versa.
Metabolic/cellular function
Changes in the GM are linked to changes in redox
metabolism (50, 101103) and metabolites produced by
the microbiota could significantly influence mitochon-
drial function (15, 16). Thus, measurements of redox
metabolism and mitochondrial function may be impor-
tant to consider when studying the human microbiome.
GM metabolites, particularly short-chain fatty acids, are
histone deacetylase inhibitors (104) and have been shown
to modulate gene expression (105), including ASD-
related genes and pathways (20), so the measurement of
gene expression may be very important in microbiome
studies.
Stool characteristics
Other stool physiochemical characteristics may also be
important including, stool pH, viscosity, short-chain
fatty acids, water versus solid content, and water holding
capacity. The relative volatility of many microbiome-
derived metabolites should be considered in sample
storage and measurement. One study found major differ-
ences in short-chain fatty acids in children with ASD
compared to controls (37).
Safety
In any clinical trial, it is important to ensure that the
treatment is safe. Given that changes in the GM have been
linked to disease and that overgrowth and infection with
particular bacteria such as C. difficile can be harmful to
individuals, a plan needs to be in place for assuring safety
of any treatment. Safety parameters discussed include C.
difficile antigen in stool, complete blood count, and liver
function tests. Furthermore, collection of biospecimens
and safety requirements need to be carefully considered
to ensure that the spread of potentially infectious waste
or material is not transmitted or transferred to personnel
involved in the study or caretakers.
Ethics
Because of the novelty of this approach, patients enrolled
in studies which manipulate the GM should be informed
that many of the treatments are based more on theory
rather than strong empirical evidence. Some of the
treatments, such as vancomycin, may only provide short-
term gain and any antibiotic treatment could, theoretically,
alter and even destabilize the GM (106110) in unpredict-
able ways that could be harmful to the host but may not be
immediately apparent. One approach toward studies of
treatments might be to enroll children with ASD who have
comorbid medical conditions, such as C. difficile infection,
into a microbiome treatment study such as a FMT study
and to determine if ASD symptoms and putative biomar-
kers (i.e. acyl-carnitines) improve in parallel with the
primary outcome.
Discussion
Overall, the working group concluded that the GM was
important to study in ASD and that there were many
promising avenues in which treatments that may influence
the GM very well could be beneficial to some children
with ASD. The group highlighted and noted the very
early stages of this research and reiterated that much
more basic and translational research will be needed
before a clear treatment(s) for ASD involving manipula-
tion of the GM will be clinically applicable.
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